PHILLIPS-MEDISIZE
8.1.2020 18:22:04 CET | Business Wire | Press release
Phillips-Medisize , a Molex company, announced expansion of its current Global Innovation and Development (GID) site in Struer, Denmark with a dedicated Manufacturing Development and Clinical build unit, which is scheduled to open in the second quarter of 2020. As a recognized global leader, Phillips-Medisize provides a wide range of custom drug delivery devices, connected health solutions and end-to-end manufacturing services worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200108005718/en/
The Phillips-Medisize manufacturing facility will be equipped to serve clients with agile set up for cleanroom assembly and molding (e.g. for clinical trials). Approximately 500 m2 of floor space from the existing 8400 m2 building will be repurposed for the cleanroom. The facility is designed to support late stage development of medium- and high-volume products and processes, under GMP and using state-of-the-art equipment.
“This expansion accelerates the manufacture of innovative, compliant and best-in-class products while reducing time to market and lowering launch risk for drug delivery device customers,” said John Horgan, Vice President, Global Sales and Marketing of Phillips-Medisize. “Furthermore, it strengthens our client focus in Scandinavia by complementing the activities of our existing GID in Struer and our newest GID in Copenhagen.”
About Phillips-Medisize:
Phillips-Medisize, LLC, a Molex company, is an end-to-end provider of innovation, development and manufacturing solutions to the pharmaceutical, diagnostics, and medical device market segments. Backed by the combined global resources of Molex and its parent company Koch Industries, Phillips-Medisize’s core advantage is the knowledge of its people to integrate design, molding, electronics, and automation, providing innovative, high-quality manufacturing solutions. For more information, please visit www.phillipsmedisize.com or www.molex.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200108005718/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 202629.7.2026 12:30:00 CEST | Press release
Compass Management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that it will release financial results for the second quarter and first half ended June 30, 2026, on August 5, 2026. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on August 5, 2026. A live webcast of the call will be available on the Compass Pathways website at: https://events.q4inc.com/attendee/246696001. The webcast will be archived for 30 days. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for tre
Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis29.7.2026 12:00:00 CEST | Press release
The European Commission approval is based on Phase 3b TRuE‑AD4 data which demonstrated that Opzelura® (ruxolitinib) cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24, and was well tolerated 1,2,3 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. "The European Commission's approval of Opzelura is an important milestone for adults in Europe living with moderate atopic dermatitis who need more treatment options," said Bill Meury, Chief Executive Officer, Incyte. "As the first steroid-free topical JAK inhibitor approved in the EU for atopic dermatitis, Opzelura offers an effective new treatment choice and reflects our commitment to advancing innovation for people with inflammatory
NTT DATA and ENGIE Announce Strategic Partnership to Power Sustainable AI and Data Center Growth29.7.2026 11:00:00 CEST | Press release
Multinational partnership to support sustainable expansion of NTT DATA’s global data center operations for AI, cloud and digital infrastructure growth.Long-term access to low-carbon and renewable energy with agreements already signed in UK, Germany and Netherlands.Power from RE100-compatible 24 MW wind farm in UK is already operational. NTT DATA, a global leader in AI, digital business and technology services, and ENGIE, a major player in the energy transition, today announced a strategic partnership to support the decarbonization, energy resilience and sustainable expansion of NTT DATA’s global data center operations. By combining ENGIE’s global leadership in renewable energy and low‑carbon solutions with NTT DATA’s infrastructure and technology services, the partnership secures long-term access to competitive renewable energy and power solutions that support the continued growth of NTT DATA’s data centers and AI infrastructure while addressing its net-zero ambitions. The partnership
Quectel Launches High-Performance FCM665D Module for Edge AI Applications29.7.2026 11:00:00 CEST | Press release
New high-performance module combines edge AI processing, Wi-Fi 6 and Bluetooth connectivity for smart home, smart building and industrial IoT applications Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the launch of the FCM665D, a high-performance Wi-Fi 6 and Bluetooth module with edge AI processing capabilities, designed for smart home, smart building and industrial IoT devices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729751874/en/ Quectel launches high-performance FCM665D module for edge AI applications Designed for products such as smart lighting, video doorbells and central control hubs, the FCM665D pairs high-performance connectivity with on-device intelligence, giving manufacturers a way to build faster, smarter, more capable devices without leaning on constant cloud connectivity. “This module has the AI capabilities and processing power to compete at the highest level
1NCE and Pessl Instruments Connect Smart Farms Worldwide29.7.2026 10:00:00 CEST | Press release
IoT specialists 1NCE and Pessl Instruments help farmers in 80 countries to connect and manage thousands of weather stations Smart farming solution improves water and fertilizer efficiency Both companies provide critical components at a 99.97% service availability 1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, and Pessl Instruments, a global leader in smart agriculture, announce today the roll-out of the METOS by Pessl Instruments weather network solution powered by 1NCE. The smart farming solution provided by Pessl Instruments connects thousands of weather stations and field sensors through a single platform, providing farmers real-time data of precipitation and soil moisture, extreme weather forecasting and crop disease risk in more than 80 countries. The main challenge for the deployment of smart farming solutions is always providing good coverage in rural areas. Thanks to 1NCE’s global connectivity service available in more
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom